Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.

Lütje S, Heskamp S, Franssen GM, Frielink C, Kip A, Hekman M, Fracasso G, Colombatti M, Herrmann K, Boerman OC, Gotthardt M, Rijpkema M.

Theranostics. 2019 May 4;9(10):2924-2938. doi: 10.7150/thno.35274. eCollection 2019.

2.

A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia.

Litti L, Rivato N, Fracasso G, Bontempi P, Nicolato E, Marzola P, Venzo A, Colombatti M, Gobbo M, Meneghetti M.

Nanoscale. 2018 Jan 18;10(3):1272-1278. doi: 10.1039/c7nr07398d.

PMID:
29292448
3.

Safe core-satellite magneto-plasmonic nanostructures for efficient targeting and photothermal treatment of tumor cells.

Bertorelle F, Pinto M, Zappon R, Pilot R, Litti L, Fiameni S, Conti G, Gobbo M, Toffoli G, Colombatti M, Fracasso G, Meneghetti M.

Nanoscale. 2018 Jan 18;10(3):976-984. doi: 10.1039/c7nr07844g.

PMID:
29264608
4.

Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.

Lütje S, Gerrits D, Molkenboer-Kuenen JD, Herrmann K, Fracasso G, Colombatti M, Boerman OC, Heskamp S.

J Nucl Med. 2018 Mar;59(3):494-501. doi: 10.2967/jnumed.117.196279. Epub 2017 Nov 16.

5.

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, Valdagni R, Mezzanzanica D, Boerman O, Canevari S, Figini M.

Oncotarget. 2017 Feb 14;8(7):10919-10930. doi: 10.18632/oncotarget.14229.

6.

Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo".

Perico ME, Grasso S, Brunelli M, Martignoni G, Munari E, Moiso E, Fracasso G, Cestari T, Naim HY, Bronte V, Colombatti M, Ramarli D.

Oncotarget. 2016 Nov 8;7(45):74189-74202. doi: 10.18632/oncotarget.12404.

7.

In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.

Mazzocco C, Fracasso G, Germain-Genevois C, Dugot-Senant N, Figini M, Colombatti M, Grenier N, Couillaud F.

Sci Rep. 2016 Mar 21;6:23314. doi: 10.1038/srep23314.

8.

Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection.

Tardivo M, Toffoli V, Fracasso G, Borin D, Dal Zilio S, Colusso A, Carrato S, Scoles G, Meneghetti M, Colombatti M, Lazzarino M.

Biosens Bioelectron. 2015 Oct 15;72:393-9. doi: 10.1016/j.bios.2015.05.026. Epub 2015 May 18.

PMID:
26025134
9.

Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.

Della Cristina P, Castagna M, Lombardi A, Barison E, Tagliabue G, Ceriotti A, Koutris I, Di Leandro L, Giansanti F, Vago R, Ippoliti R, Flavell SU, Flavell DJ, Colombatti M, Fabbrini MS.

Microb Cell Fact. 2015 Feb 13;14:19. doi: 10.1186/s12934-015-0202-z.

10.

PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.

Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, Figini M, Cingarlini S, Colombatti M, Zanovello P, Rosato A.

PLoS One. 2014 Oct 3;9(10):e109427. doi: 10.1371/journal.pone.0109427. eCollection 2014.

11.

Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).

Tykvart J, Navrátil V, Sedlák F, Corey E, Colombatti M, Fracasso G, Koukolík F, Bařinka C, Sácha P, Konvalinka J.

Prostate. 2014 Dec;74(16):1674-90. doi: 10.1002/pros.22887. Epub 2014 Sep 27.

PMID:
25262926
12.

Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.

Lütje S, van Rij CM, Franssen GM, Fracasso G, Helfrich W, Eek A, Oyen WJ, Colombatti M, Boerman OC.

Contrast Media Mol Imaging. 2015 Jan-Feb;10(1):28-36. doi: 10.1002/cmmi.1596. Epub 2014 Apr 25.

PMID:
24764162
13.

Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.

Lütje S, Rijpkema M, Franssen GM, Fracasso G, Helfrich W, Eek A, Oyen WJ, Colombatti M, Boerman OC.

J Nucl Med. 2014 Jun;55(6):995-1001. doi: 10.2967/jnumed.114.138180. Epub 2014 Apr 3.

14.

Magneto-plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging.

Amendola V, Scaramuzza S, Litti L, Meneghetti M, Zuccolotto G, Rosato A, Nicolato E, Marzola P, Fracasso G, Anselmi C, Pinto M, Colombatti M.

Small. 2014 Jun 25;10(12):2476-86. doi: 10.1002/smll.201303372. Epub 2014 Mar 11. Erratum in: Small. 2014 Oct 15;10(19):3823.

PMID:
24619736
15.

Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen.

Schmidt S, Gericke B, Fracasso G, Ramarli D, Colombatti M, Naim HY.

PLoS One. 2013 Jun 19;8(6):e66193. doi: 10.1371/journal.pone.0066193. Print 2013.

16.

Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems.

Selvestrel F, Moret F, Segat D, Woodhams JH, Fracasso G, Echevarria IM, Baù L, Rastrelli F, Compagnin C, Reddi E, Fedeli C, Papini E, Tavano R, MacKenzie A, Bovis M, Yaghini E, MacRobert AJ, Zanini S, Boscaini A, Colombatti M, Mancin F.

Nanoscale. 2013 Jul 7;5(13):6106-16. doi: 10.1039/c3nr00402c. Epub 2013 May 31.

PMID:
23728482
17.

A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.

Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S, Figini M.

Eur J Cancer. 2013 Jun;49(9):2223-32. doi: 10.1016/j.ejca.2013.01.024. Epub 2013 Feb 20.

PMID:
23433847
18.

Cloning and characterization of canine prostate-specific membrane antigen.

Schmidt S, Fracasso G, Colombatti M, Naim HY.

Prostate. 2013 May;73(6):642-50. doi: 10.1002/pros.22605. Epub 2013 Jan 28.

PMID:
23359458
19.

The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.

Ben Jemaa A, Sallami S, Ramarli D, Colombatti M, Oueslati R.

Inflammation. 2013 Jun;36(3):643-50. doi: 10.1007/s10753-012-9586-7.

PMID:
23250823
20.

Ectopic expression of the heterotrimeric G15 protein in pancreatic carcinoma and its potential in cancer signal transduction.

Giovinazzo F, Malpeli G, Zanini S, Parenti M, Piemonti L, Colombatti M, Valenti MT, Dalle Carbonare L, Scarpa A, Sinnett-Smith J, Rozengurt E, Bassi C, Innamorati G.

Cell Signal. 2013 Mar;25(3):651-9. doi: 10.1016/j.cellsig.2012.11.018. Epub 2012 Nov 29.

PMID:
23200847
21.

Plasmonic nanostructures for SERRS multiplexed identification of tumor-associated antigens.

Meneghetti M, Scarsi A, Litti L, Marcolongo G, Amendola V, Gobbo M, Di Chio M, Boscaini A, Fracasso G, Colombatti M.

Small. 2012 Dec 21;8(24):3733-8. doi: 10.1002/smll.201201196. Epub 2012 Aug 24. No abstract available.

PMID:
22927257
22.

Reductive activation of type 2 ribosome-inactivating proteins is promoted by transmembrane thioredoxin-related protein.

Pasetto M, Barison E, Castagna M, Della Cristina P, Anselmi C, Colombatti M.

J Biol Chem. 2012 Mar 2;287(10):7367-73. doi: 10.1074/jbc.M111.316828. Epub 2012 Jan 6.

23.

Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.

Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A.

Mol Ther. 2011 Oct;19(10):1858-66. doi: 10.1038/mt.2011.144. Epub 2011 Jul 26.

24.

Lymphocyte phenotypic subsets in umbilical cord blood compared to peripheral blood from related mothers.

Chirumbolo S, Ortolani R, Veneri D, Raffaelli R, Peroni D, Pigozzi R, Colombatti M, Vella A.

Cytometry B Clin Cytom. 2011 Jul-Aug;80(4):248-53. doi: 10.1002/cyto.b.20588. Epub 2011 Feb 16. No abstract available.

25.

IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.

Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S.

Vaccine. 2010 Apr 30;28(20):3548-57. doi: 10.1016/j.vaccine.2010.03.007. Epub 2010 Mar 19.

PMID:
20304037
26.

The puzzling uniqueness of the heterotrimeric G15 protein and its potential beyond hematopoiesis.

Giannone F, Malpeli G, Lisi V, Grasso S, Shukla P, Ramarli D, Sartoris S, Monsurró V, Krampera M, Amato E, Tridente G, Colombatti M, Parenti M, Innamorati G.

J Mol Endocrinol. 2010 May;44(5):259-69. doi: 10.1677/JME-09-0134. Epub 2010 Feb 11. Review.

PMID:
20150327
27.

Pichia pastoris as a host for secretion of toxic saporin chimeras.

Lombardi A, Bursomanno S, Lopardo T, Traini R, Colombatti M, Ippoliti R, Flavell DJ, Flavell SU, Ceriotti A, Fabbrini MS.

FASEB J. 2010 Jan;24(1):253-65. doi: 10.1096/fj.08-118042. Epub 2009 Sep 28.

PMID:
19786581
28.

Late generation lentiviral vectors: evaluation of inflammatory potential in human airway epithelial cells.

Copreni E, Nicolis E, Tamanini A, Bezzerri V, Castellani S, Palmieri L, Giri MG, Vella A, Colombatti M, Rizzotti P, Conese M, Cabrini G.

Virus Res. 2009 Sep;144(1-2):8-17. doi: 10.1016/j.virusres.2009.03.012. Epub 2009 Apr 2.

PMID:
19447514
29.

The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways.

Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D.

PLoS One. 2009;4(2):e4608. doi: 10.1371/journal.pone.0004608. Epub 2009 Feb 26. Erratum in: PLoS ONE. 2009;4(3). doi: 10.1371/annotation/f290f38a-4f71-43ad-b988-9f8d5a7329fe.

30.

Chemical conjugation of DeltaF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions.

Norez C, Pasetto M, Dechecchi MC, Barison E, Anselmi C, Tamanini A, Quiri F, Cattel L, Rizzotti P, Dosio F, Cabrini G, Colombatti M.

Am J Physiol Lung Cell Mol Physiol. 2008 Aug;295(2):L336-47. doi: 10.1152/ajplung.00059.2008. Epub 2008 May 30.

31.

Different glycoforms of prostate-specific membrane antigen are intracellularly transported through their association with distinct detergent-resistant membranes.

Castelletti D, Alfalah M, Heine M, Hein Z, Schmitte R, Fracasso G, Colombatti M, Naim HY.

Biochem J. 2008 Jan 1;409(1):149-57.

PMID:
17935484
32.

MPB-07 reduces the inflammatory response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells.

Dechecchi MC, Nicolis E, Bezzerri V, Vella A, Colombatti M, Assael BM, Mettey Y, Borgatti M, Mancini I, Gambari R, Becq F, Cabrini G.

Am J Respir Cell Mol Biol. 2007 May;36(5):615-24. Epub 2006 Dec 29.

PMID:
17197571
33.

N-terminal deletion affects catalytic activity of saporin toxin.

Bonini F, Traini R, Comper F, Fracasso G, Tomazzolli R, Dalla Serra M, Colombatti M.

J Cell Biochem. 2006 Aug 1;98(5):1130-9.

PMID:
16775836
34.

Detection of ricin and other ribosome-inactivating proteins by an immuno-polymerase chain reaction assay.

Lubelli C, Chatgilialoglu A, Bolognesi A, Strocchi P, Colombatti M, Stirpe F.

Anal Biochem. 2006 Aug 1;355(1):102-9. Epub 2006 May 19.

PMID:
16762307
35.

A fluorescence-based assay for the reductase activity of protein disulfide isomerase.

Tomazzolli R, Serra MD, Bellisola G, Colombatti M, Guella G.

Anal Biochem. 2006 Mar 1;350(1):105-12. Epub 2005 Dec 20.

PMID:
16434015
36.

Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells.

Colombara M, Antonini V, Riviera AP, Mainiero F, Strippoli R, Merola M, Fracasso G, Poffe O, Brutti N, Tridente G, Colombatti M, Ramarli D.

J Immunol. 2005 Nov 15;175(10):7021-8.

37.

Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing.

Castelletti D, Fracasso G, Alfalah M, Cingarlini S, Colombatti M, Naim HY.

J Biol Chem. 2006 Feb 10;281(6):3505-12. Epub 2005 Oct 12.

38.

Peptide analogues of a T-cell epitope of ricin toxin A-chain prevent agonist-mediated human T-cell response.

Castelletti D, Colombatti M.

Int Immunol. 2005 Apr;17(4):365-72. Epub 2005 Feb 21.

PMID:
15724064
39.

Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.

Rheumatol Int. 2006 Jan;26(3):209-14. Epub 2004 Dec 31.

PMID:
15627197
40.

Immunotoxins and other conjugates: preparation and general characteristics.

Fracasso G, Bellisola G, Castelletti D, Tridente G, Colombatti M.

Mini Rev Med Chem. 2004 Jun;4(5):545-62. Review.

PMID:
15180510
41.

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Castelletti D, Fracasso G, Righetti S, Tridente G, Schnell R, Engert A, Colombatti M.

Clin Exp Immunol. 2004 May;136(2):365-72.

42.

Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase.

Bellisola G, Fracasso G, Ippoliti R, Menestrina G, Rosén A, Soldà S, Udali S, Tomazzolli R, Tridente G, Colombatti M.

Biochem Pharmacol. 2004 May 1;67(9):1721-31.

PMID:
15081871
43.

Anti-tumor effects of toxins targeted to the prostate specific membrane antigen.

Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M.

Prostate. 2002 Sep 15;53(1):9-23.

PMID:
12210476
44.

Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.

Tommasi M, Castelletti D, Pasti M, Fracasso G, Lorenzetti I, Sartoris S, Pera C, Ferrara GB, Tridente G, Colombatti M.

Clin Exp Immunol. 2001 Sep;125(3):391-400.

45.

Human MBP-specific T cells regulate IL-6 gene expression in astrocytes through cell-cell contacts and soluble factors.

Colombatti M, Moretto G, Tommasi M, Fiorini E, Poffe O, Colombara M, Tanel R, Tridente G, Ramarli D.

Glia. 2001 Sep;35(3):224-33.

PMID:
11494413
46.

Pharmacokinetics of intrathecal transferrin-ricin a chain immunotoxin.

Candiani C, Tommasi M, Fracasso G, Lorenzetti I, Adami A, Benoni G, Tridente G, Colombatti M.

Life Sci. 2001 Jun 8;69(3):335-46.

PMID:
11441924
47.

Synthesis of monensin derivatives and their effect on the activity of ricin A-chain immunotoxins.

Colombatti M, Dosio F.

Methods Mol Biol. 2001;166:55-70. Review. No abstract available.

PMID:
11217376
48.
49.

Effect of therapeutic macromolecules in spheroids.

Fracasso G, Colombatti M.

Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):159-78. Review.

PMID:
11033304
50.

Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates.

Lorenzetti I, Meneguzzi A, Fracasso G, Potrich C, Costantini L, Chiesa E, Legname G, Menestrina G, Tridente G, Colombatti M.

Int J Cancer. 2000 May 15;86(4):582-9.

Supplemental Content

Loading ...
Support Center